REG - Credit Suisse (Eur) JSC NAC Kazatomprom - Exercise of Greenshoe - Kazatomprom

NAK Kazatomprom AOAnnouncement

07/12/2018 17:25

RNS Number : 8839J
Credit Suisse Securities (Eur) Ltd
07 December 2018
 


7th December 2018
 
 
 
Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.
 
Joint Stock Company "National Atomic Company "Kazatomprom"
 
Exercise of Over-Aallotment Option
 
 
 
Further to the post-stabilisation announcement of 30 November 2018, Credit Suisse Securities (Europe) Limited, acting as a stabilisating manager in connection with the initial public offering ("Offering") of JSC NAC "Kazatomprom" (the "Company") has exercised the over-allotment option (the "Over-allotment option") granted by JSC Sovereign Wealth Fund "Samruk-Kazyna" in respect to 4,142,863 global depositary receipts representing ordinary shares of the Company (the "Over-Allotment GDRs") at the offer price of US$11.60 per Over-Allotment GDR.
 
Following the exercise of the Over-allotment Option, the final size of the Offering was US$448,858,613. Excluding the portion sold in the Offering on the stock exchange of the Astana International Financial Centre, the final size of the Offering was US$384,584,474 (or 33,153,834 GDRs).    
 
 
 
This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction. This announcement is not an offer of securities for sale into the United States. The securities have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There will be no public offer of securities in the United States.                  




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
OFBLLFFDFLLDIIT